Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00. The firm maintained a Buy ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

TikTok's ban could be a big win for its tech rivals. Here are the companies that have the most to gain.